07-05-2025
Ireland ready to be global leader in high-value biopharma services
A new BioPharma Business Services (BBS) strategy will be launched today for Ireland's biopharmaceutical and chemical sector.
The strategy aims to position Ireland as a hub for global services by leveraging the country's position as a leading manufacturing location and diversifying and strengthening the industry ecosystem in the country.
BioPharmaChem Ireland (BPCI), the Ibec group that represents the sector, launches the strategy at the Impact 2025 conference and awards taking place at the Killashee House Hotel in Naas.
Nearly 9,500 professionals, representing close to 20% of total BioPharmaChem employment in Ireland, work in BBS. BBS is one of the fastest growing industry segments, expected to grow by 10% by 2027.
"Our new strategy focuses on value stream enhancement, talent development, cutting-edge digital and AI infrastructure, and a vibrant ecosystem, to position Ireland as the global leader in innovative, high-value biopharma services," said Pfizer finance and global business services vice president Aoife Allen, who is the chair of BPCI's BBS steering committee.
More than 300 life science professionals are attending the conference in Naas. "It's an important time for the ecosystem to come together to understand the challenges and explore opportunities to support the development of the industry," said BioPharmaChem Ireland director Sinead Keogh.
"To ensure competitiveness, it is vital that Ireland prioritises investments in critical areas such as skills and talent, energy and infrastructure, public sector research and innovation, and regulatory simplicity. We welcome the new Government's commitment to a National Life Sciences Strategy and Action Plan on Competitiveness and Productivity. These priorities must remain at the forefront of policy agendas to secure the sector's long-term resilience."
